false 0001401040 0001401040 2022-05-04 2022-05-04
 


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
__________________
 
Date of Report (Date of earliest event reported):   May 4, 2022
___________________
 
DIAMEDICA THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)
 
British Columbia
001-36291
Not Applicable
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
(IRS Employer
Identification No.)
Two Carlson Parkway, Suite 260
Minneapolis, Minnesota
55447
(Address of principal executive offices)
(Zip Code)
(763) 312-6755
(Registrant’s telephone number, including area code)
 
Not Applicable
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Voting common shares, no par value per share
DMAC
The Nasdaq Stock Market LLC
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
  Emerging growth company 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 
 


 
 

 
Item 2.02.         Results of Operations and Financial Condition.
 
On May 4, 2022, DiaMedica Therapeutics Inc. (the “Company”) announced its consolidated financial results for the three months ended March 31, 2022. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and the information set forth therein is incorporated herein by reference and constitutes a part of Item 2.02 of this report.
 
The information contained in Item 2.02 of this report and Exhibit 99.1 to this report shall not be deemed to be "filed" with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be incorporated by reference into any filings made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in such filing.
 
Item 9.01         Financial Statements and Exhibits.
 
(d)  Exhibits.
 
Exhibit No.
 
Description
99.1
 
Press Release dated May 4, 2022 providing a business update and reporting first quarter 2022 financial results (furnished herewith)
104
 
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL
 
 

 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
DIAMEDICA THERAPEUTICS INC.
By:
/s/ Scott Kellen
Scott Kellen
Chief Financial Officer and Secretary
 
Dated: May 4, 2022